As of close of business last night, CytomX Therapeutics Inc’s stock clocked out at $2.54, up 12.89% from its previous closing price of $2.25. On the day, 6828901 shares were traded.
Ratios:
To gain a deeper understanding of CTMX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on November 14, 2022, Downgraded its rating to Market Perform and sets its target price to $2.60 from $3 previously.
On July 07, 2022, Wedbush Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $6 to $2.
Piper Sandler Downgraded its Overweight to Neutral on July 07, 2022, whereas the target price for the stock was revised from $10 to $1.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 20 when McCarthy Sean A. sold 13,551 shares for $1.38 per share. The transaction valued at 18,710 led to the insider holds 454,704 shares of the business.
ROWLAND LLOYD A sold 4,077 shares of CTMX for $5,629 on Dec 20. The General Counsel now owns 97,996 shares after completing the transaction at $1.38 per share. On Dec 20, another insider, BELVIN MARCIA, who serves as the SVP, Chief Scientific Officer of the company, sold 4,077 shares for $1.38 each. As a result, the insider received 5,628 and left with 155,124 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 170.82M and an Enterprise Value of -8.23M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.80. Its current Enterprise Value per Revenue stands at -0.09 whereas that against EBITDA is 0.63.
Stock Price History:
Over the past 52 weeks, CTMX has reached a high of $2.44, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is 1.5482, while the 200-Day Moving Average is calculated to be 1.5099.
Shares Statistics:
It appears that CTMX traded 472.07K shares on average per day over the past three months and 1.25M shares per day over the past ten days. A total of 66.23M shares are outstanding, with a floating share count of 65.75M. Insiders hold about 1.85% of the company’s shares, while institutions hold 48.84% stake in the company. Shares short for CTMX as of Feb 15, 2024 were 1.3M with a Short Ratio of 2.76, compared to 1.32M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.95% and a Short% of Float of 1.96%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.03 for the current quarter, with a high estimate of $0.12 and a low estimate of -$0.24, while EPS last year was -$0.43. The consensus estimate for the next quarter is $0, with high estimates of $0.11 and low estimates of -$0.1.
Analysts are recommending an EPS of between $0.11 and -$0.28 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is -$0.19, with 6 analysts recommending between $0.2 and -$0.72.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $21.04M. It ranges from a high estimate of $31.1M to a low estimate of $10M. As of the current estimate, CytomX Therapeutics Inc’s year-ago sales were $946k, an estimated increase of 2,124.10% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $20.92M, a decrease of -11.00% less than the figure of $2,124.10% in the same quarter last year. There is a high estimate of $31.1M for the next quarter, whereas the lowest estimate is $12.5M.
A total of 7 analysts have provided revenue estimates for CTMX’s current fiscal year. The highest revenue estimate was $105.71M, while the lowest revenue estimate was $85M, resulting in an average revenue estimate of $95.62M. In the same quarter a year ago, actual revenue was $53.16M, up 79.90% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $78.34M in the next fiscal year. The high estimate is $104M and the low estimate is $50M. The average revenue growth estimate for next year is down -18.10% from the average revenue estimate for this year.
